Pub. Date : 2015 May
PMID : 25809021
8 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner. | Rosuvastatin Calcium | apolipoprotein B | Homo sapiens |
| 2 | Dose-associated effects of rosuvastatin on the metabolism of apolipoprotein (apo) B-100 in triacylglycerol rich lipoprotein (TRL, d < 1.019 g/ml) and low density lipoprotein (LDL) and of apoA-I in high density lipoprotein (HDL) were assessed in subjects with combined hyperlipidemia. | Rosuvastatin Calcium | apolipoprotein B | Homo sapiens |
| 3 | Our primary hypothesis was that maximal dose rosuvastatin would decrease the apoB-100 production rate (PR), as well as increase apoB-100 fractional catabolic rate (FCR). | Rosuvastatin Calcium | apolipoprotein B | Homo sapiens |
| 4 | Our primary hypothesis was that maximal dose rosuvastatin would decrease the apoB-100 production rate (PR), as well as increase apoB-100 fractional catabolic rate (FCR). | Rosuvastatin Calcium | apolipoprotein B | Homo sapiens |
| 5 | Rosuvastatin at 5 and 40 mg/day decreased LDL cholesterol by 44 and 54% (both P < 0.0001), triacylglycerol by 14% (ns) and 35% (P < 0.01), apoB by 30 and 36% (both P < 0.0001), respectively, and had no significant effects on HDL cholesterol or apoA-I levels. | Rosuvastatin Calcium | apolipoprotein B | Homo sapiens |
| 6 | Rosuvastatin 5 and 40 mg/day increased TRL apoB-100 FCR by 36 and 46% (both ns) and LDL apoB-100 by 63 and 102% (both P < 0.05), respectively. | Rosuvastatin Calcium | apolipoprotein B | Homo sapiens |
| 7 | Rosuvastatin 5 and 40 mg/day increased TRL apoB-100 FCR by 36 and 46% (both ns) and LDL apoB-100 by 63 and 102% (both P < 0.05), respectively. | Rosuvastatin Calcium | apolipoprotein B | Homo sapiens |
| 8 | Our data indicate that maximal dose rosuvastatin treatment in subjects with combined hyperlipidemia resulted in significant increases in the catabolism of LDL apoB-100, with no significant effects on apoB-100 production or HDL apoA-I kinetics. | Rosuvastatin Calcium | apolipoprotein B | Homo sapiens |